Psychedelic Therapy Is Imminent. Will the FDA Get It Right?—DoubleBlind Magazine

Read article—Amber Barnato, a professor of medicine, is featured in coverage of an FDA hearing on psychedelic therapy, urging caution as regulators consider expanded access. "I believe that FDA approval of access for terminally ill patients is ethically defensible… But ongoing comparative effectiveness research remains critical," Barnato said.